Vanderhyden, B.C. and Dorward, A.M. 2016. Reference Module in Biomedical Sciences.
Zhang, Hui Liu, Tao Zhang, Zhen Payne, Samuel H. Zhang, Bai McDermott, Jason E. Zhou, Jian-Ying Petyuk, Vladislav A. Chen, Li Ray, Debjit Sun, Shisheng Yang, Feng Chen, Lijun Wang, Jing Shah, Punit Cha, Seong Won Aiyetan, Paul Woo, Sunghee Tian, Yuan Gritsenko, Marina A. Clauss, Therese R. Choi, Caitlin Monroe, Matthew E. Thomas, Stefani Nie, Song Wu, Chaochao Moore, Ronald J. Yu, Kun-Hsing Tabb, David L. Fenyö, David Bafna, Vineet Wang, Yue Rodriguez, Henry Boja, Emily S. Hiltke, Tara Rivers, Robert C. Sokoll, Lori Zhu, Heng Shih, Ie-Ming Cope, Leslie Pandey, Akhilesh Zhang, Bing Snyder, Michael P. Levine, Douglas A. Smith, Richard D. Chan, Daniel W. and Rodland, Karin D. 2016. Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. Cell, Vol. 166, Issue. 3, p. 755.
Kan, Casina W. S. Howell, Viive M. Hahn, Michael A. and Marsh, Deborah J. 2015. Genomic alterations as mediators of miRNA dysregulation in ovarian cancer. Genes, Chromosomes and Cancer, Vol. 54, Issue. 1, p. 1.
Howell, Viive M. 2014. Genetically engineered mouse models for epithelial ovarian cancer: Are we there yet?. Seminars in Cell & Developmental Biology, Vol. 27, p. 106.
Altman, Alon D Nelson, Gregg S Ghatage, Prafull McIntyre, John B Capper, David Chu, Pamela Nation, Jill G Karnezis, Anthony N Han, Guangming Kalloger, Steve E and Köbel, Martin 2013. The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. Modern Pathology, Vol. 26, Issue. 9, p. 1255.
Conklin, Chris MJ and Gilks, C Blake 2013. Differential diagnosis and clinical relevance of ovarian carcinoma subtypes. Expert Review of Obstetrics & Gynecology, Vol. 8, Issue. 1, p. 67.
Gurung, Ananta Hung, Tawny Morin, Jason and Gilks, C Blake 2013. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. Histopathology, Vol. 62, Issue. 1, p. 59.
Bromley, Amy B. Altman, Alon D. Chu, Pamela Nation, Jill G. Nelson, Gregg S. Ghatage, Praful Kalloger, Steve E. Han, Guangming and Köbel, Martin 2012. Architectural Patterns of Ovarian/Pelvic High-grade Serous Carcinoma. International Journal of Gynecological Pathology, Vol. 31, Issue. 5, p. 397.
Lafontaine, Julie Rodier, Francis Ouellet, Véronique Mes-Masson, Anne-Marie and Blagosklonny, Mikhail V. 2012. Necdin, a p53-Target Gene, Is an Inhibitor of p53-Mediated Growth Arrest. PLoS ONE, Vol. 7, Issue. 2, p. e31916.
Malisic, Emina Jankovic, Radmila and Jakovljevic, Ksenija 2012. Detection and genotyping of human papillomaviruses and their role in the development of ovarian carcinomas. Archives of Gynecology and Obstetrics, Vol. 286, Issue. 3, p. 723.
Smith, Cassandra L. Oh, Herin and Stamenović, Dimitrije 2012. Encyclopedia of Analytical Chemistry.
Dobrzycka, B. Terlikowski, S. J. Kinalski, M. Kowalczuk, O. Niklinska, W. and Chyczewski, L. 2011. Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers. Annals of Oncology, Vol. 22, Issue. 5, p. 1133.
Jazaeri, Amir A. Bryant, Jennifer L. Park, Hong Li, Hui Dahiya, Neetu Stoler, Mark H. Ferriss, James Stuart and Dutta, Anindya 2011. Molecular Requirements for Transformation of Fallopian Tube Epithelial Cells into Serous Carcinoma. Neoplasia, Vol. 13, Issue. 10, p. 899.
Köbel, Martin and Huntsman, David 2011. Molecular Pathology of Ovarian Carcinomas. Surgical Pathology Clinics, Vol. 4, Issue. 1, p. 275.
Köbel, Martin Turbin, Dmitry Kalloger, Steve E. Gao, Dongxia Huntsman, David G. and Gilks, C. Blake 2011. Biomarker Expression in Pelvic High-grade Serous Carcinoma. International Journal of Gynecological Pathology, Vol. 30, Issue. 4, p. 366.
Lee, Peng Jain, Shilpa Pincus, Matthew R. and Xu, Ruliang 2011. Henry's Clinical Diagnosis and Management by Laboratory Methods.
McAlpine, J.N. El Hallani, S. Lam, S.F. Kalloger, S.E. Luk, M. Huntsman, D.G. MacAulay, C. Gilks, C.B. Miller, D.M. and Lane, P.M. 2011. Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: A promising step towards screening and early detection. Gynecologic Oncology, Vol. 120, Issue. 3, p. 385.
Schlosshauer, Peter W. Deligdisch, Liane Penault-Llorca, Frédérique Fatemi, Delaram Qiao, Rui Yao, Shen Pearl, Meghan Yang, Zhen Sheng, Tao and Dong, Jianli 2011. Loss of p16INK4A Expression in Low-grade Ovarian Serous Carcinomas. International Journal of Gynecological Pathology, Vol. 30, Issue. 1, p. 22.
Vereczkey, Ildikó Serester, Orsolya Dobos, Judit Gallai, Mónika Szakács, Orsolya Szentirmay, Zoltán and Tóth, Erika 2011. Molecular Characterization of 103 Ovarian Serous and Mucinous Tumors. Pathology & Oncology Research, Vol. 17, Issue. 3, p. 551.
Cooke, S L Ng, C K Y Melnyk, N Garcia, M J Hardcastle, T Temple, J Langdon, S Huntsman, D and Brenton, J D 2010. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene, Vol. 29, Issue. 35, p. 4905.
Ovarian carcinomas show more morphological heterogeneity than adenocarcinomas of any other body site. It has recently become clear that the morphologically defined subtypes of ovarian carcinoma are distinct diseases, with different risk factors, molecular events during oncogenesis, likelihood of spread, responses to chemotherapy, and outcomes. This review focuses on molecular abnormalities (in genes expressing BRCA1/2, TP53 and RB1/CCND1/CDKN2A/E2F) found in high-grade serous carcinomas of the ovary, which account for most ovarian cancer deaths. These highly aggressive but chemosensitive tumours are associated with perturbation of molecular pathways leading to genomic instability and extreme mutability and present unique challenges in oncological research and practice.
This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
Email your librarian or administrator to recommend adding this journal to your organisation's collection.